Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress
Rhea-AI Summary
Enliven Therapeutics (Nasdaq: ELVN) will host a webcast conference call on June 11, 2026 at 8:30 a.m. ET to discuss updated Phase 1 ENABLE clinical trial data for ELVN-001 in previously treated chronic myeloid leukemia, following an oral presentation at the EHA 2026 Congress.
Positive
- None.
Negative
- None.
News Market Reaction – ELVN
In the Jun 4 session, ELVN declined 1.50%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 21 | Investor conferences | Neutral | -1.7% | Participation in upcoming oncology and healthcare investor conferences with webcasts. |
| May 12 | Clinical data update | Positive | +6.8% | Additional positive Phase 1 ENABLE data for ELVN-001 accepted for EHA 2026 oral. |
| May 07 | Q1 2026 earnings | Positive | +1.1% | Q1 2026 results with $452.4M cash and plans for Phase 3 ENABLE-2. |
| Mar 03 | FY 2025 earnings | Positive | +4.3% | Positive initial Phase 1b ELVN-001 data and strong year-end cash position. |
| Feb 25 | Investor conference | Neutral | +1.2% | Announcement of TD Cowen fireside chat with 90-day webcast archive. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent ELVN-001 and earnings updates have generally seen aligned, modestly positive price reactions.
Over recent months, Enliven’s trajectory has centered on ELVN-001 for CML and its path to the Phase 3 ENABLE-2 pivotal trial. Earnings on Feb 25 and May 7 highlighted strong cash balances (e.g., $452.4M) and positive Phase 1b data, with shares reacting positively. The May 12 EHA 2026 oral presentation announcement for additional ELVN-001 Phase 1 data also drew a 6.85% gain. Today’s webcast notice builds on that EHA-focused clinical narrative ahead of presenting updated Phase 1 ENABLE results.
Key Terms
chronic myeloid leukemia medical
bcr::abl1 medical
cp-cml medical
atp-competitive inhibitor medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Enliven will host a webcast conference call on June 11, at 8:30 a.m. ET
Company webcast and conference call information
Date and time: Thursday, June 11, 8:30 a.m. ET / 2:30 p.m. CEST
Access details: To participate in the live event, please register using this link. Following registration, participants will have access to dial-in numbers and a unique passcode should they prefer to participate by phone. The event and accompanying slides can also be accessed by visiting the investor relations section of the Company's website at https://ir.enliventherapeutics.com/. An archived webcast will be available on the Company's website following the event.
Details of the 2026 EHA oral presentation are as follows:
Title: ENABLE: Updated Efficacy and Safety Results of ELVN-001, a Novel Selective ATP-Competitive Inhibitor of BCR::ABL1, in Patients with Previously Treated CP-CML
Presenter: Dennis Kim, M.D.
Session Title: s416 Chronic myeloid leukemia – Clinical
Location: A12 Hall
Abstract Number: S164
Presentation Date/Time: June 11, 5:45 p.m. - 6:00 p.m. CEST / 11:45 a.m. ET
The abstract is available on the EHA website. Following the EHA oral presentation, a copy will be available on the "Program Presentations & Publications" section of the Company's website at www.enliventherapeutics.com.
About the ENABLE Trial
The ENABLE study (NCT05304377) is a Phase 1 study of ELVN-001 in patients with previously treated CML. ENABLE is a dose escalation and expansion trial designed to evaluate safety and tolerability and to determine the recommended dose for further clinical evaluation of ELVN-001 in patients with CML with and without T315I mutations that is relapsed, refractory or intolerant to tyrosine kinase inhibitors (TKIs). Secondary endpoints include pharmacokinetics, major molecular response (MMR) by central quantitative reverse transcriptase polymerase chain reaction, duration of MMR, BCR::ABL1 transcript levels and complete hematologic response.
About ELVN-001
ELVN-001 is a potent, highly selective, potentially best-in-class small molecule kinase inhibitor designed to specifically target the BCR::ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia. ELVN-001, a highly selective active-site TKI, has a mechanism of action that is complementary to allosteric BCR::ABL1 inhibitors, which may play an increasingly important role in the standard of care. ELVN-001 was designed to have activity against the T315I mutation, the most common BCR::ABL1 mutation, which confers resistance to nearly all approved TKIs, as well as activity against mutations known to confer resistance to allosteric BCR::ABL1 inhibitors.
About Enliven Therapeutics
Enliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. Enliven aims to address existing and emerging unmet needs with a precision medicine approach that improves survival and enhances overall well-being. Enliven's discovery process combines deep insights into clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. To learn more, visit www.enliventherapeutics.com and connect with us on LinkedIn and X.
View original content to download multimedia:https://www.prnewswire.com/news-releases/enliven-therapeutics-to-host-webcast-conference-call-to-discuss-phase-1-elvn-001-clinical-data-being-presented-at-eha-2026-congress-302790671.html
SOURCE Enliven Therapeutics, Inc.